Antibe Therapeutics Inc.

ATBPF · OTC
Analyze with AI
12/31/2023
9/30/2023
6/30/2023
3/31/2023
Operating Activities
Net Income-$4,213-$5,008-$5,786-$3,548
Dep. & Amort.$0$0$0$0
Deferred Tax$0$0$0$0
Stock-Based Comp.$442-$79$416$451
Change in WC-$2-$1,345$786-$537
Other Non-Cash-$72$61$349$250
Operating Cash Flow-$3,845-$6,432-$4,584-$3,384
Investing Activities
PP&E Inv.$0$0$0$2
Net Acquisitions$0$0$0-$240
Inv. Purchases$0-$3,313-$10,109-$10,311
Inv. Sales/Matur.$10,166$5,095$16,731$10,000
Other Inv. Act.$875$2$7-$1
Investing Cash Flow$11,041$1,782$6,622-$549
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$0$0$0$0
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$0$0$0$159
Financing Cash Flow$0$0$0$159
Forex Effect$0$0$0$0
Net Chg. in Cash$7,196-$4,650$2,038-$3,774
Supplemental Information
Beg. Cash$4,143$8,793$6,755$10,529
End Cash$11,339$4,143$8,793$6,755
Free Cash Flow-$3,845-$6,432-$4,584-$3,382